S5-26 - One Month Later: Looking Back at MASLD/MASH Coverage From The Liver Meeting 2024
Send us a text 00:00:00 – Surf’s Up: Season 5 Episode 26 - Last month, close to 8,000 hepatology stakeholders convened in San Diego for The Liver Meeting 2024. Hepatology Key Opinion Leader Naim Alkhouri, Novo Nordisk International Vice President for Medicines Michelle Long, and patient advocates Jeff McIntyre from the Global Liver Institute and Michael Betel from the Fatty Liver Alliance join Jörn Schattenberg and Roger Green to discuss highlights. 00:03:23 - Introduction and Groundbreaker...
20 Dec 20241h 11min
S5 - E25 - Reviewing Expert Recommendations on the Use of Resmetirom
Send us a text 00:00:00 - Surf's Up: Season 5 Episode 25 On July 20, Clinical Gastroenterology and Hepatology released the paper, Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to non-cirrhotic Advanced Fibrosis. Corresponding author Maru Rinella joins the Surfers to share key points from the recommendations and offer her thoughts on what lay behind them. 00:02:26 - Introduction and Groundbreaker...
9 Aug 202442min
S4 - E24.5 - SurfingMASH Question of The Week: Keys to Improving Provider-Patient Communication
Send us a text Two weeks ago, the SurfingMASH Question of the Week asked, "What structural or educational changes do you anticipate will significantly improve Provider-Patient communication? Will these changes require more from the provider and more from the patient?" Today, S5 E23 panelists Mike Betel and José Willemse join Roger Green to review the three answers we received. Of the three questions from audience members, one from a patient/patient advocate suggested greater honesty, b...
8 Aug 202420min
S5 - E24.4 - EASL Congress Six Weeks Later: Jeff McIntyre's Key Implications for GLI
Send us a text In the second half of Roger Green's interview with Global Liver Institute Vice President, Liver Programs Jeff McIntyre, Jeff discusses the implications of his key EASL Congress takeaways for GLI and other patient advocacy groups. To Jeff, this trend makes patient advocates a more valuable player in the clinical trial design process, particularly when coupled with the FDA's increasing focus on diversity in trial populations. This will become particularly important becaus...
8 Aug 202418min
S5 - E24.3 - EASL Congress Six Weeks Later: Jeff McIntyre's Key Takeaways
Send us a text This conversation contains the first half of Roger Green's interview with Global Liver Institute Vice President, Liver Programs Jeff McIntyre, during which the two discuss what Jeff considered the key strategic takeaways for GLI from the various EASL Congress presentations, abstracts and discussions. Jeff focuses on the "overriding sense of optimism" coming from the multiple pieces of positive drug data. He cites the data on Boehringer Ingelheim's survodutide, the follow...
7 Aug 202412min
S5 - E24.2 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Implications
Send us a text In the second half of Roger Green's interview with PharmaNest Founder and CEO Mathieu Petitjean, Matt discusses the implications of his key EASL Congress takeaways for PharmaNest. Matt starts this discussion with a simple question: Will biopsy-based analyses become part of a surrogate endpoint? As he points out, they are not today, and creating the necessary data might require a significant effort. If not, they are unlikely to remain relevant to the large, Phase 3 trial...
7 Aug 202410min
S5 - E24.1 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Takeaways
Send us a text This conversation contains the first half of Roger Green's interview with PharmaNest Founder and CEO Mathieu Petitjean. After Matt tells the audience a little about his background and PhramaNest, the two discuss what Matt considered the key strategic takeaways for PharmaNest from the various EASL Congress presentations, abstracts and discussions. Before answering the question, Matt describes the core services his company offers: "PharmaNest specializes in digital patholo...
7 Aug 202417min
S5 - E24 - A view of MASLD: Looking back at EASL Congress from six weeks later
Send us a text 00:00:00 - Surf's Up: Season 5 Episode 24 This week's episode on MASLD lessons from the EASL Congress 2024 includes three separate elements: individual interviews with PharmaNext Founder and CEO Mathieu Petitjean and Global Liver Institute Vice President of Liver Programs Jeff McIntyre, followed by a discussion with patient advocates Mike Betel of the Fatty Liver Alliance and José Willemse from the Netherlands, now supporting EASL. 00:02:45 - Introduction Rog...
3 Aug 20241h 16min
